Call opens: 10th November 2021 (13:00 GMT)
Deadline to apply: 26th January 2022 (13:00 GMT)
The NIHR Invention for Innovation (i4i) Programme is inviting applications for a Dementia specific funding stream aimed at the research and development of digital approaches for the early detection, diagnosis and stratification of individuals with dementia.
The i4i Programme supports the research and development of innovative medical technologies that have demonstrated proof-of-concept and have a clear developmental pathway towards new products for ultimate NHS use. Dementia research is an ongoing priority for the Department of Health and Social Care (DHSC) and for the NIHR. There is an identified need for robust assessments to validate digital biomarkers as accurate and precise diagnostic or prognostic methods that correlate with established assessments, and to evaluate their clinical and patient use through appropriate studies.
This call encourages multi-disciplinary teams across different organisations and healthcare settings to address these priorities, harness innovation and support a step forward in the management of dementia.
Digital biomarkers
Digital biomarkers are objective physiological and behavioural measurements collected through technologies (software and hardware), electronic health records or other clinical datasets that can be assessed online or in primary care.
There are two principal applications that this funding call seeks to address:
- Digital biomarkers that may improve the capability to accurately predict, detect and diagnose dementia, enabling the earliest possible coordination of care.
- Digital biomarkers that may facilitate the stratification of individuals at greater risk of developing dementia, or help determine the subtype and prognosis of dementia patients.
The competition will support proposals covering any of the following aims:
- the large-scale pragmatic validation of digital biomarkers for dementia (DBDs);
- the development of DBDs into advanced diagnostic or prognostic prototypes or products;
- clinical evaluations toward near market-ready solutions.
For more information and to apply please click here